Research and Markets (http://www.researchandmarkets.com/research/pj8wjs/myasthenia) has announced the addition of the "Myasthenia Gravis-Pipeline Insights, 2016" report to their offering.

Myasthenia Gravis-Pipeline Insights, 2016 provides in depth insights on the pipeline drugs and their development activities around the Myasthenia Gravis. The report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration.

Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details.

The report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Myasthenia Gravis.

The report also assesses the Myasthenia Gravis therapeutics by Monotherapy, Combination products, molecule type and Route of Administration.

Scope

  • The report provides competitive pipeline landscape of Myasthenia Gravis
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Myasthenia Gravis pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Myasthenia Gravis and also provide company profiling
  • The report also gives the information of dormant and discontinued pipeline projects
  • Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Key Topics Covered:

  1. Myasthenia Gravis Overview
  2. Myasthenia Gravis Pipeline Therapeutics
  3. Myasthenia Gravis Therapeutics under Development by Companies
  4. Myasthenia Gravis Filed and Phase III Products
  5. Comparative Analysis
  6. Myasthenia Gravis Phase II Products
  7. Comparative Analysis
  8. Myasthenia Gravis Phase I and IND Filed Products
  9. Comparative Analysis
  10. Myasthenia Gravis Discovery and Pre-Clinical Stage Products
  11. Comparative Analysis
  12. Drug Candidate Profiles
  13. Myasthenia Gravis - Therapeutics Assessment
  14. Assessment by Monotherapy Products
  15. Assessment by Combination Products
  16. Assessment by Route of Administration
  17. Assessment by Molecule Type
  18. Myasthenia Gravis - Discontinued Products
  19. Myasthenia Gravis - Dormant Products
  20. Companies Involved in Therapeutics Development for Myasthenia Gravis

For more information visit http://www.researchandmarkets.com/research/pj8wjs/myasthenia